We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is HealthEquity's Improving Profitability Enough to Offset Key Risks?
Read MoreHide Full Article
Key Takeaways
HQY beat Q1 fiscal 2027 EPS estimates; revenue rose 7% to $354.6M on broad-based gains.
HQY gross margin jumped 450 bps to 72.3% and operating margin rose 390 bps to 29% despite higher costs.
HQY lifted FY2027 revenues to $1.41-$1.42B and EPS to $4.66-$4.73; yield and cyber risks persist.
HealthEquity, Inc. (HQY - Free Report) is benefiting from expanding margins, improving operating leverage and technology-driven efficiency initiatives. The company is also investing in security enhancements and automation tools to strengthen customer service and fraud prevention capabilities. However, despite the improving fundamentals, HealthEquity reflects a balanced risk-reward profile.
The key question for investors is whether stronger profitability and higher guidance can outweigh ongoing exposure to custodial yield fluctuations, cybersecurity-related uncertainties and competitive pressures.
HQY’s Strong Fiscal First-Quarter Performance Supports Outlook
HealthEquity delivered adjusted earnings per share of $1.24 in the first quarter of fiscal 2027, surpassing the Zacks Consensus Estimate by 11.7%. Earnings increased 28% year over year, driven by operating leverage and continued business momentum.
Revenues rose 7% year over year to $354.6 million and modestly exceeded expectations. Growth was supported by contributions from service, custodial and interchange revenues, demonstrating broad-based strength across the business.
Profitability remained a key highlight during the quarter. Gross profit increased 14.3% year over year to $256.3 million, while gross margin expanded 450 basis points to 72.3%.
Although HealthEquity continued to invest in growth and technology initiatives, margin performance remained strong. Sales and marketing expenses increased 3.3% year over year to $26.8 million, technology and development expenses rose 10.3% year over year to $67.8 million, and general and administrative expenses climbed 21.9% year over year to $31.1 million. Even with these investments, operating income increased 23.9%, resulting in a 390-basis-point expansion in operating margin to 29%.
Image Source: Zacks Investment Research
HQY’s Raised Guidance Reflects Confidence
Management raised its fiscal 2027 outlook following the strong start to the year. Revenues are now expected to be in the range of $1.41-$1.42 billion, up from the prior guidance of $1.405-$1.415 billion.
Adjusted earnings per share are now projected to be between $4.66 and $4.73 compared with the earlier range of $4.56-$4.65. The higher outlook reflects stronger participation in enhanced-rate offerings, benefits from the company's hedging strategy designed to reduce custodial yield volatility and continued operational improvements.
Solid Financial Position Supports Flexibility
HealthEquity ended the quarter with cash and cash equivalents of $265.4 million. Total debt declined to $942.6 million from $957.4 million at fiscal 2026-end, reflecting ongoing balance-sheet improvement.
The company's interest coverage ratio improved to 6.4 times from 5.9 times at the end of fiscal 2026. Meanwhile, operating cash flow increased significantly to $97.5 million from $64.7 million in the year-ago period, highlighting stronger cash generation and improving earnings quality.
HQY Share Repurchases and Capital Allocation
HealthEquity’s active share repurchase plan is part of the current setup and can support per-share outcomes when operating performance is also improving. Buybacks tend to matter most when they are funded by sustained cash generation and when the business outlook remains stable enough to avoid a reversal in capital priorities.
Risks Remain on the Radar
Despite the favorable operating trends, investors should continue monitoring several risk factors. HealthEquity remains sensitive to changes in custodial yields and client contract dynamics. In addition, cybersecurity-related litigation and regulatory developments continue to create uncertainty.
The company also operates in a competitive environment where larger players such as UnitedHealth Group (UNH - Free Report) and Webster Financial (WBS - Free Report) possess significant scale and distribution advantages.
Investment Takeaway
HealthEquity is executing well, as evidenced by expanding margins, rising cash flow and increased fiscal 2027 guidance. Management's focus on automation, fraud reduction and security enhancements is supporting profitability while positioning the business for long-term growth.
However, exposure to custodial yield fluctuations, cybersecurity overhangs and competitive pressures prevents a more aggressive stance at this stage. Consequently, HealthEquity's current Zacks Rank #3 (Hold) appears appropriate as investors await further confirmation that recent margin gains and guidance improvements can be sustained. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
HQY’s Sales & EPS Picture
In fiscal 2027, HQY is expected to experience growth of 7.8% in revenues. On the profitability front, earnings per share are expected to improve 17.8% year over year.
Image Source: Zacks Investment Research
HQY’s Valuation Picture
HQY currently trades at a forward 12-months price-to-sales ratio of 5.2X, above its industry’s current level of 0.5X.
Image Source: Zacks Investment Research
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is HealthEquity's Improving Profitability Enough to Offset Key Risks?
Key Takeaways
HealthEquity, Inc. (HQY - Free Report) is benefiting from expanding margins, improving operating leverage and technology-driven efficiency initiatives. The company is also investing in security enhancements and automation tools to strengthen customer service and fraud prevention capabilities. However, despite the improving fundamentals, HealthEquity reflects a balanced risk-reward profile.
The key question for investors is whether stronger profitability and higher guidance can outweigh ongoing exposure to custodial yield fluctuations, cybersecurity-related uncertainties and competitive pressures.
HQY’s Strong Fiscal First-Quarter Performance Supports Outlook
HealthEquity delivered adjusted earnings per share of $1.24 in the first quarter of fiscal 2027, surpassing the Zacks Consensus Estimate by 11.7%. Earnings increased 28% year over year, driven by operating leverage and continued business momentum.
Revenues rose 7% year over year to $354.6 million and modestly exceeded expectations. Growth was supported by contributions from service, custodial and interchange revenues, demonstrating broad-based strength across the business.
HQY Margin Expansion Highlights Operating Leverage
Profitability remained a key highlight during the quarter. Gross profit increased 14.3% year over year to $256.3 million, while gross margin expanded 450 basis points to 72.3%.
Although HealthEquity continued to invest in growth and technology initiatives, margin performance remained strong. Sales and marketing expenses increased 3.3% year over year to $26.8 million, technology and development expenses rose 10.3% year over year to $67.8 million, and general and administrative expenses climbed 21.9% year over year to $31.1 million. Even with these investments, operating income increased 23.9%, resulting in a 390-basis-point expansion in operating margin to 29%.
Image Source: Zacks Investment Research
HQY’s Raised Guidance Reflects Confidence
Management raised its fiscal 2027 outlook following the strong start to the year. Revenues are now expected to be in the range of $1.41-$1.42 billion, up from the prior guidance of $1.405-$1.415 billion.
Adjusted earnings per share are now projected to be between $4.66 and $4.73 compared with the earlier range of $4.56-$4.65. The higher outlook reflects stronger participation in enhanced-rate offerings, benefits from the company's hedging strategy designed to reduce custodial yield volatility and continued operational improvements.
Solid Financial Position Supports Flexibility
HealthEquity ended the quarter with cash and cash equivalents of $265.4 million. Total debt declined to $942.6 million from $957.4 million at fiscal 2026-end, reflecting ongoing balance-sheet improvement.
The company's interest coverage ratio improved to 6.4 times from 5.9 times at the end of fiscal 2026. Meanwhile, operating cash flow increased significantly to $97.5 million from $64.7 million in the year-ago period, highlighting stronger cash generation and improving earnings quality.
HQY Share Repurchases and Capital Allocation
HealthEquity’s active share repurchase plan is part of the current setup and can support per-share outcomes when operating performance is also improving. Buybacks tend to matter most when they are funded by sustained cash generation and when the business outlook remains stable enough to avoid a reversal in capital priorities.
Risks Remain on the Radar
Despite the favorable operating trends, investors should continue monitoring several risk factors. HealthEquity remains sensitive to changes in custodial yields and client contract dynamics. In addition, cybersecurity-related litigation and regulatory developments continue to create uncertainty.
The company also operates in a competitive environment where larger players such as UnitedHealth Group (UNH - Free Report) and Webster Financial (WBS - Free Report) possess significant scale and distribution advantages.
Investment Takeaway
HealthEquity is executing well, as evidenced by expanding margins, rising cash flow and increased fiscal 2027 guidance. Management's focus on automation, fraud reduction and security enhancements is supporting profitability while positioning the business for long-term growth.
However, exposure to custodial yield fluctuations, cybersecurity overhangs and competitive pressures prevents a more aggressive stance at this stage. Consequently, HealthEquity's current Zacks Rank #3 (Hold) appears appropriate as investors await further confirmation that recent margin gains and guidance improvements can be sustained. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
HQY’s Sales & EPS Picture
In fiscal 2027, HQY is expected to experience growth of 7.8% in revenues. On the profitability front, earnings per share are expected to improve 17.8% year over year.
Image Source: Zacks Investment Research
HQY’s Valuation Picture
HQY currently trades at a forward 12-months price-to-sales ratio of 5.2X, above its industry’s current level of 0.5X.
Image Source: Zacks Investment Research